ASCO® GU 2025 Insights: Neoadjuvant Durvalumab + Chemo in Operable High-Risk UTUC - iNDUCT Trial | VuMedi

Find latest Bladder Cancer videos · 200+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

This video is featured in the Insights from 2025 ASCO® GU Annual Meeting

Insights from 2025 ASCO® GU Annual Meeting

ASCO® GU 2025 Insights: Neoadjuvant Durvalumab + Chemo in Operable High-Risk UTUC - iNDUCT Trial

By Insights from 2025 ASCO® GU Annual Meeting FEATURING Nadine Houede

By Insights from 2025 ASCO® GU Annual Meeting FEATURING Nadine Houede

42 views

February 25, 2025

Comments 0

Login to view comments. Click here to Login